Form 4: Moderna CFO James Mock Executes RSU Vesting Transactions

Moderna CFO James Mock acquired shares through the vesting of restricted stock units and withheld a portion to cover tax obligations.

Summary

• Chief Financial Officer James M. Mock acquired 773 shares of common stock on May 27, 2026, and 328 shares on May 28, 2026, via the vesting of restricted stock units (RSUs).
• A total of 533 shares were withheld by the company to satisfy tax withholding obligations associated with these vestings.
• Following these transactions, James M. Mock holds 58,316 shares of Moderna common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard executive compensation activity.

Positives

• The transactions represent routine equity compensation vesting rather than discretionary open-market sales.
• The CFO maintains a significant equity stake of 58,316 shares, aligning interests with shareholders.

Negatives

• The withholding of shares for tax purposes results in a minor reduction of the total potential share count held by the executive.

Risks

• None identified; these are standard administrative transactions related to executive compensation.

Future Outlook

The filing does not provide forward-looking business guidance, as it is a disclosure of insider equity transactions.

Industry Context

StockSavvy.ai notes that routine RSU vesting and tax-related share withholding are standard practices for C-suite executives in the biotechnology sector and do not typically signal changes in corporate strategy or outlook.

Comparison to Industry Standards

• The transaction structure is consistent with standard executive compensation practices at large-cap pharmaceutical companies like Pfizer, Merck, and Amgen.

Stakeholder Impact

• Minimal impact on shareholders as these transactions are part of pre-existing compensation agreements.

Next Steps

• Future vesting of remaining restricted stock units according to the established quarterly schedule.

Key Dates

Keywords

Moderna, MRNA, Form 4, Insider Trading, Executive Compensation, Restricted Stock Units